EDIT: Editas Medicine Inc

Новости EDIT

• The Motley Fool 09:04 Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
• The Motley Fool 12:15 2 Beaten-Down Stocks to Avoid
• Benzinga 17:59 Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly (NYSE:LLY), Verve Therapeutics (NASDAQ:VERV)
• The Motley Fool 14:07 Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
• Investor's Business Daily 13:14 Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
• Investing 06:12 Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema
• Investing 20:55 nucana plc announces annual report release and upcoming agm
• Investing 21:40 editas medicine amends stock plan and increases authorized shares
• The Motley Fool 10:00 1 Stock Down 97% That Could Double, According to Wall Street
• Investing 17:59 Chardan cuts Prime Medicine stock target to $12, maintains Buy
• Investing 13:50 Cantor maintains Overweight on Astria stock with $47 target
• Investing 13:45 Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
• Investing 01:03 Editas Medicine at BofA Securities 2025: In Vivo Gene Editing Focus
• Seeking Alpha 08:44 CRISPR And Intellia: Balancing Market Uncertainty Against Pipeline Catalysts (NASDAQ:CRSP)
• Seeking Alpha 20:07 Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)
• Seeking Alpha 16:19 Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
• Seeking Alpha 22:01 Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript